Shares of Stryker Co. (NYSE:SYK) have been given an average rating of “Hold” by the twenty-five brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $161.72.
Several research analysts have recently commented on SYK shares. Wells Fargo & Co raised their price target on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. SunTrust Banks restated a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Cowen set a $166.00 price target on Stryker and gave the stock a “buy” rating in a research report on Sunday, October 29th. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Finally, Canaccord Genuity raised their price target on Stryker from $155.00 to $162.00 and gave the stock a “buy” rating in a research report on Friday, October 27th.
In other Stryker news, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total value of $479,021.52. Following the sale, the insider now directly owns 9,100 shares in the company, valued at $1,460,823. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,840 shares of company stock worth $2,749,989. Insiders own 7.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Chemical Bank raised its stake in Stryker by 24.1% in the fourth quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock valued at $2,003,000 after buying an additional 2,515 shares in the last quarter. Green Square Capital LLC raised its stake in Stryker by 148.5% in the fourth quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock valued at $871,000 after buying an additional 3,350 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in Stryker by 7.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after buying an additional 385 shares in the last quarter. Colonial Trust Advisors raised its stake in Stryker by 40.9% in the fourth quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock valued at $5,246,000 after buying an additional 9,836 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its position in shares of Stryker by 7.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock worth $8,909,000 after purchasing an additional 3,912 shares in the last quarter. Institutional investors own 74.49% of the company’s stock.
Shares of Stryker (NYSE SYK) traded up $2.74 during trading on Friday, reaching $161.70. The company had a trading volume of 983,059 shares, compared to its average volume of 1,470,000. The stock has a market capitalization of $60,580.00, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 2.29 and a beta of 0.70. Stryker has a 52 week low of $127.19 and a 52 week high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business posted $1.78 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts predict that Stryker will post 7.12 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is currently 38.37%.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.